What Is Cartalax Peptide? (Same Compound, Multiple Names)

What Is Cartalax Peptide? (Same Compound, Multiple Names)

Researchers ordering peptides for cartilage and connective tissue studies encounter the same confusion every time: one supplier lists 'Cartalax', another lists 'Cartalax peptide', and a third might reference it by its sequence identifier. The assumption. Often wrong. Is that these are different compounds or formulations. They're not. The Cartalax peptide and Cartalax reference the same bioregulator tripeptide (Ala-Glu-Asp) synthesised under protocols established by the St. Petersburg Institute of Bioregulation and Gerontology. The naming variance exists purely at the commercial and publication level. The molecular identity remains constant across both terms.

Our team has clarified this exact question for hundreds of researchers placing orders. The confusion isn't about the peptide itself. It's about inconsistent nomenclature across research institutions, suppliers, and clinical literature. Once you understand that 'Cartalax peptide' and 'Cartalax' describe identical molecular structures, procurement becomes straightforward.

What is Cartalax peptide. Is it the same as Cartalax?

Yes, Cartalax peptide is the same compound as Cartalax. Both refer to the tripeptide sequence alanine-glutamic acid-aspartic acid (Ala-Glu-Asp), a bioregulator peptide developed under Vladimir Khavinson's research framework at the St. Petersburg Institute of Bioregulation and Gerontology. The term 'peptide' is often appended for clarity in research contexts, distinguishing it from other bioactive molecules, but the molecular structure, synthesis pathway, and intended mechanism remain identical regardless of which name appears on the label or in published studies.

The key point most suppliers omit: Cartalax (with or without 'peptide' as a suffix) isn't a brand name or proprietary formulation. It's a descriptor for a specific amino acid sequence. Any synthesis that produces Ala-Glu-Asp in the correct sequential order is producing Cartalax, whether the final product is labelled 'Cartalax', 'Cartalax peptide', or referenced by its molecular composition. The naming variation reflects publication conventions and supplier branding choices, not differences in the compound itself. This article covers why the dual naming exists, what differentiates legitimate synthesis from mislabelled products, and how to verify you're ordering the correct tripeptide sequence regardless of the name on the vial.

Why Cartalax Has Two Common Names

The dual naming convention. 'Cartalax' versus 'Cartalax peptide'. Originates from how bioregulator compounds were catalogued during their initial development in Russia during the 1980s and 1990s. Vladimir Khavinson's research team at the St. Petersburg Institute of Bioregulation and Gerontology assigned short names (Cartalax, Vesugen, Pinealon) to differentiate compounds by their target tissue systems rather than their full chemical sequences. When these compounds entered broader research circulation outside Russian-language publications, Western suppliers added 'peptide' as a suffix to clarify the molecular class. Distinguishing them from small molecules, herbs, or other supplement categories that non-specialist researchers might confuse them with.

The addition of 'peptide' serves a functional purpose in research procurement: it signals to lab managers and institutional buyers that the product requires peptide-specific handling (lyophilised storage, reconstitution protocols, refrigerated shipping). A researcher ordering 'Cartalax' without the peptide designation might inadvertently place it in improper storage or handle it like a stable small molecule. The naming difference also appears in published literature. Early Russian studies reference 'Cartalax' while Western replications and reviews frequently use 'Cartalax peptide' to align with standard biochemical nomenclature. Neither term holds priority. Both are correct, and both describe Ala-Glu-Asp synthesised for cartilage and connective tissue bioregulation research.

What matters for procurement is sequence verification, not name consistency. A supplier selling 'Cartalax peptide' and another selling 'Cartalax' are offering the same compound if both deliver Ala-Glu-Asp at stated purity (typically ≥98% by HPLC). The confusion arises when researchers assume the naming variation implies formulation differences. Longer peptide chains, altered sequences, or proprietary modifications. It doesn't. At Real Peptides, we use 'Cartalax peptide' in our catalogue to maintain consistency with broader biochemical terminology, but the sequence we synthesise matches the original Khavinson Institute protocols exactly.

The Molecular Identity Behind Both Names

Cartalax. Whether labelled with or without 'peptide'. Is a tripeptide composed of three amino acids in sequential order: alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp). The molecular formula is C10H15N3O8, with a molecular weight of approximately 305.24 g/mol. This structure is not proprietary. It's a defined chemical sequence that any peptide synthesis facility can replicate using solid-phase peptide synthesis (SPPS) with Fmoc (fluorenylmethyloxycarbonyl) protection chemistry. The sequence itself determines the bioregulatory activity, targeting cartilage tissue through mechanisms involving gene expression modulation in chondrocytes and extracellular matrix protein synthesis.

The original research published by Khavinson and colleagues in peer-reviewed Russian journals during the 1990s established that this specific tripeptide sequence demonstrated selective uptake in cartilage tissue when administered systemically in animal models. The proposed mechanism involves the peptide entering the nucleus of target cells and binding to specific DNA regions, upregulating expression of genes involved in collagen type II synthesis and proteoglycan production. The structural proteins that give cartilage its tensile strength and compressive resistance. This mechanism is dose-dependent and tissue-specific, meaning higher concentrations don't arbitrarily affect non-cartilage tissues at the same rate.

Purity and sequence accuracy are the only variables that matter when comparing Cartalax from different suppliers. A product labelled 'Cartalax peptide' synthesised to 99.2% purity with confirmed Ala-Glu-Asp sequencing is functionally identical to a product labelled 'Cartalax' meeting the same specifications. The variance in research outcomes comes from dosing protocols, reconstitution handling, and experimental design. Not from the name on the vial. We've reviewed synthesis reports from multiple suppliers, and the compounds that perform consistently in tissue culture and animal studies all share one characteristic: verified sequence fidelity confirmed by mass spectrometry. If a supplier cannot produce an HPLC chromatogram and mass spec report confirming the Ala-Glu-Asp sequence, the naming convention is irrelevant. The product is not reliable for research use.

Cartalax Peptide: Research Applications and Mechanism

The research applications for Cartalax peptide centre on cartilage repair, joint tissue regeneration, and connective tissue homeostasis studies. Published studies. Predominantly from Russian research institutions but increasingly replicated in Western labs. Demonstrate that Cartalax administration in rodent models leads to measurable increases in cartilage thickness, improved histological markers of extracellular matrix integrity, and reduced inflammatory cytokine expression in osteoarthritis models. The peptide does not act as a direct anti-inflammatory agent like NSAIDs. Instead, it appears to shift chondrocyte gene expression toward anabolic (building) pathways rather than catabolic (breakdown) pathways that dominate in degenerative joint conditions.

One key study published in the Bulletin of Experimental Biology and Medicine (2015) examined Cartalax effects on aged rats with naturally occurring cartilage degeneration. Researchers administered 100 micrograms of Cartalax peptide subcutaneously three times per week for eight weeks. Histological analysis showed significant preservation of cartilage architecture compared to control groups, with increased safranin-O staining (indicating proteoglycan density) and reduced fibrillation scores on the cartilage surface. The peptide group also demonstrated improved weight-bearing capacity in functional tests, suggesting the structural improvements translated to mechanical function.

The dose-response relationship matters critically in experimental design. Studies using doses below 50 micrograms per administration showed minimal histological changes, while doses above 200 micrograms did not produce proportionally greater effects. Suggesting a plateau in bioactivity at higher concentrations. Reconstitution in sterile bacteriostatic water at concentrations between 1–5 mg/mL maintains stability for up to 28 days when refrigerated at 2–8°C. Researchers using Cartalax in cell culture studies typically apply concentrations between 0.1–10 micrograms per millilitre of culture medium, with optimal chondrocyte proliferation observed at 1 microgram/mL in multiple independent studies.

Our experience with researchers using Cartalax Peptide in joint tissue studies confirms that reconstitution errors cause more variability in results than sequence differences between suppliers. The peptide is sensitive to pH extremes during reconstitution. Mixing with anything other than neutral-pH bacteriostatic water or sterile saline risks partial denaturation. This is where the 'peptide' suffix in the name serves a practical purpose: it reminds researchers that standard peptide handling protocols apply, unlike stable small molecules that tolerate rougher handling.

Cartalax Peptide vs Cartalax: Comparison

Before purchasing, researchers often compare products labelled differently to determine if formulation or quality differences justify price variations. The following table clarifies what actually differs between products labelled 'Cartalax peptide' and 'Cartalax'.

Amino Acid Sequence

Ala-Glu-Asp (tripeptide)

No. Identical molecular structure

Molecular Weight

~305.24 g/mol

No. Same compound

Synthesis Method

Solid-phase peptide synthesis (SPPS)

No. Standard synthesis pathway

Target Tissue Selectivity

Cartilage, connective tissue

No. Same bioregulatory target

Typical Purity Range

≥98% by HPLC

No. Purity standards are identical

Reconstitution Protocol

Bacteriostatic water, 2–8°C storage

No. Handling requirements identical

Research Application Scope

Joint tissue studies, cartilage repair models, aging research

No. Experimental use cases overlap completely

Naming Convention Origin

Western biochemical nomenclature (adds 'peptide' for clarity)

Original Russian Institute naming (short form)

Yes. But only affects catalogue search terms, not the compound itself

The bottom line: if two suppliers both deliver Ala-Glu-Asp at verified purity with proper lyophilisation and cold-chain shipping, the name on the label ('Cartalax peptide' versus 'Cartalax') is irrelevant to research outcomes. Sequence fidelity, purity verification, and handling integrity determine experimental reliability. Not nomenclature.

Key Takeaways

Cartalax peptide and Cartalax refer to the identical tripeptide sequence (Ala-Glu-Asp). The naming difference reflects publication conventions and supplier branding, not molecular variation.

The compound was developed under Vladimir Khavinson's bioregulator research framework at the St. Petersburg Institute of Bioregulation and Gerontology, targeting cartilage and connective tissue repair through gene expression modulation in chondrocytes.

Verified sequence fidelity (confirmed by HPLC and mass spectrometry) and purity ≥98% are the only procurement criteria that matter. The presence or absence of 'peptide' in the product name does not indicate formulation differences.

Research dosing in rodent models typically ranges from 50–200 micrograms per administration subcutaneously, with optimal chondrocyte proliferation in cell culture observed at 1 microgram/mL.

Reconstitution in bacteriostatic water at neutral pH and refrigerated storage at 2–8°C maintains peptide stability for up to 28 days. Improper reconstitution causes more experimental variability than supplier differences.

Published studies demonstrate increased cartilage thickness, improved proteoglycan density, and reduced fibrillation scores in osteoarthritis models when Cartalax is administered over 8–12 week periods.

What If: Cartalax Peptide Scenarios

What If I Ordered 'Cartalax' But Needed 'Cartalax Peptide' for a Study Protocol?

You have the correct compound. No reorder is necessary. The naming variation does not reflect a formulation difference. Verify that the product certificate of analysis (CoA) confirms the Ala-Glu-Asp sequence and purity ≥98% by HPLC. If those specifications match your protocol requirements, the product you received is suitable for your study regardless of whether the label reads 'Cartalax' or 'Cartalax peptide'. The only scenario requiring a reorder is if the CoA shows sequence deviation, purity below specification, or contamination. None of which correlate with the name used in the product description.

What If the Peptide Arrives as a Powder Instead of Pre-Mixed?

This is the expected and preferred format. Cartalax peptide is synthesised and shipped as lyophilised (freeze-dried) powder to maximise shelf stability during storage and transport. Pre-mixed solutions degrade significantly faster. Lyophilised peptides stored at -20°C maintain structural integrity for 12–24 months, while reconstituted solutions lose potency within 28 days even under refrigeration. Reconstitute only the amount needed for your immediate experimental window. Add sterile bacteriostatic water slowly down the side of the vial, swirl gently to dissolve (never shake vigorously), and refrigerate at 2–8°C immediately after mixing.

What If I Can't Find Sequence Verification in the Product Documentation?

Request the certificate of analysis (CoA) directly from the supplier before using the product in any experiment. Reputable peptide suppliers provide HPLC chromatograms and mass spectrometry reports confirming the amino acid sequence for every batch. If the supplier cannot produce these documents, the product is not suitable for research use. Sequence fidelity is non-negotiable for reproducible results. At Real Peptides, every batch of Cartalax Peptide ships with a CoA confirming Ala-Glu-Asp sequencing and purity testing results. This documentation is not optional. It's the baseline standard for any compound entering a controlled study.

What If the Cartalax Peptide Shows No Effect in My Cartilage Culture Study?

Review three variables before concluding the peptide is ineffective: dosing concentration, incubation duration, and reconstitution handling. Published studies showing positive results in chondrocyte cultures use concentrations between 0.1–10 micrograms/mL, with optimal effects at 1 microgram/mL after 48–72 hours of continuous exposure. Concentrations below 0.1 micrograms/mL may fall below the threshold for measurable gene expression changes. Verify that your reconstituted solution was stored at 2–8°C and used within 28 days. Peptides stored improperly or past stability windows lose bioactivity without visible degradation. If all handling was correct and dosing matched published protocols, the issue may be baseline chondrocyte viability or culture medium composition rather than the peptide itself.

The Unvarnished Truth About Cartalax Naming

Here's the honest answer: the dual naming exists because suppliers and researchers across different regions adopted inconsistent terminology, and no regulatory body standardised the nomenclature. 'Cartalax peptide' and 'Cartalax' mean the same thing. Ala-Glu-Asp synthesised for bioregulator research. But the confusion persists because it benefits suppliers who can charge different prices for identically sequenced products under different names. Researchers waste time comparing formulations that don't exist, questioning whether one version is 'stronger' or 'more pure' when both should meet identical ≥98% purity standards if synthesised correctly.

The practical implication: stop shopping by name and start verifying by sequence. A supplier offering 'Premium Cartalax Peptide' at twice the price of standard 'Cartalax' is selling the same tripeptide unless they provide mass spec data proving a difference. They won't. Because there isn't one. The compound either matches Ala-Glu-Asp at verified purity or it doesn't. Everything else is marketing. If the certificate of analysis confirms sequence fidelity and purity, the name on the vial is irrelevant to your experimental outcomes.

Verifying Authentic Cartalax Regardless of Label Name

Authenticity verification starts with the certificate of analysis, not the product name. Every legitimate peptide supplier provides batch-specific HPLC chromatograms showing retention time and peak purity, plus mass spectrometry data confirming the molecular weight matches the expected value for Ala-Glu-Asp (~305.24 g/mol). These documents should reference the specific batch number printed on your vial. Generic CoAs that apply to 'all batches' are insufficient. If the supplier states they 'test periodically' rather than per-batch, find a different supplier.

Visual inspection catches obvious failures but misses most quality issues. Legitimate lyophilised Cartalax appears as a white to off-white powder with no discolouration, clumping, or moisture inside the vial. The seal should be intact with no cracks or punctures. Once reconstituted, the solution should be clear to slightly opalescent. Cloudiness or visible particulates indicate contamination or improper lyophilisation. However, peptides can look perfect and still be degraded or incorrectly sequenced, which is why documentation review cannot be skipped.

The synthesis method matters less than the verification. Both Fmoc-based solid-phase peptide synthesis and liquid-phase synthesis can produce high-purity Cartalax if performed correctly. What separates research-grade from unreliable product is post-synthesis purification and testing. HPLC purification to remove truncated sequences and side products, followed by mass spec confirmation that the final product matches the target structure. Suppliers who skip purification or rely on thin-layer chromatography instead of HPLC produce peptides with 85–90% purity at best, where the remaining 10–15% consists of deletion sequences, oxidised variants, or synthesis byproducts that interfere with experimental outcomes.

Our standard at Real Peptides for all bioregulator peptides, including Cartalax, is small-batch synthesis with exact amino-acid sequencing confirmed by both HPLC and mass spectrometry. We don't synthesise one large batch and distribute it indefinitely. Each production run undergoes independent purity verification before shipping. This approach costs more than bulk synthesis, but it eliminates the batch-to-batch variability that causes researchers to question whether a failed replication stems from experimental design or compromised peptide quality.

Cartalax peptide and Cartalax describe the same molecular entity. A tripeptide targeting cartilage bioregulation developed under rigorous synthesis protocols. The naming variance reflects inconsistent supplier terminology across research markets, not a meaningful difference in formulation or potency. Researchers selecting between products labelled differently should prioritise sequence verification over brand preference. A supplier providing transparent batch documentation, HPLC-confirmed purity, and proper cold-chain handling delivers reliable Cartalax regardless of whether 'peptide' appears in the product name. The compound's research utility depends entirely on synthesis fidelity and handling integrity. The label is just a label.

Frequently Asked Questions

Cartalax peptide and Cartalax are identical — both refer to the tripeptide sequence Ala-Glu-Asp with no formulation differences. The term ‘peptide’ is added by some suppliers to clarify the molecular class, but the sequence, synthesis method, and bioregulatory mechanism remain the same. Any supplier delivering Ala-Glu-Asp at ≥98% purity is providing the same compound regardless of the name on the label.

Request the certificate of analysis (CoA) from your supplier, which should include HPLC chromatograms showing purity and mass spectrometry data confirming the molecular weight matches Ala-Glu-Asp (~305.24 g/mol). The CoA must reference the specific batch number on your vial — generic certificates are insufficient. Legitimate suppliers provide this documentation for every batch without requiring special requests.

Reconstitute lyophilised Cartalax with sterile bacteriostatic water at concentrations between 1–5 mg/mL, adding the water slowly down the vial side and swirling gently to dissolve. Store the reconstituted solution at 2–8°C and use within 28 days. Unreconstituted lyophilised powder should be stored at -20°C, where it maintains stability for 12–24 months. Never shake vigorously during reconstitution — it denatures the peptide structure.

Price differences between identically sequenced products reflect supplier branding and market positioning, not formulation variation. If two suppliers both deliver Ala-Glu-Asp at verified ≥98% purity with proper documentation, the naming difference does not justify price disparity. Researchers should compare certificates of analysis and synthesis methods rather than product names when evaluating cost differences.

Rodent studies typically administer 50–200 micrograms of Cartalax subcutaneously per dose, three times per week for 8–12 weeks. Cell culture studies use concentrations between 0.1–10 micrograms/mL, with optimal chondrocyte proliferation observed at 1 microgram/mL after 48–72 hours of exposure. Doses below 50 micrograms show minimal effects, while doses above 200 micrograms do not produce proportionally greater results.

Cartalax is classified as a research-grade peptide, not an FDA-approved therapeutic. All current evidence comes from preclinical animal models and in vitro cell culture studies — no large-scale human clinical trials have been conducted to establish safety or efficacy for medical use. Researchers purchase Cartalax exclusively for laboratory investigation into cartilage repair mechanisms, not for human administration.

Reconstituted Cartalax maintains structural integrity for up to 28 days when stored at 2–8°C in bacteriostatic water. Beyond 28 days, peptide degradation accelerates even under refrigeration, leading to reduced bioactivity in experimental applications. For studies requiring longer timelines, reconstitute only the volume needed for each experimental phase rather than preparing large batches in advance.

Cartalax enters chondrocytes and binds to specific DNA regions, upregulating genes involved in collagen type II synthesis and proteoglycan production — the structural proteins that provide cartilage with tensile strength and compressive resistance. This shifts cellular activity from catabolic (breakdown) pathways toward anabolic (building) pathways, resulting in measurable increases in extracellular matrix density and improved cartilage architecture in rodent models.

No — the molecular weight is identical at approximately 305.24 g/mol for both naming variants because they describe the same tripeptide sequence (Ala-Glu-Asp). Mass spectrometry confirmation of this molecular weight is a standard verification step in certificates of analysis. Any product showing a significantly different molecular weight is either mislabelled or synthesised incorrectly.

Freezing reconstituted peptides can cause ice crystal formation that disrupts the molecular structure, leading to partial denaturation and reduced bioactivity. If a vial was accidentally frozen, thaw it slowly at 2–8°C and inspect for visible precipitation or cloudiness — if either is present, discard the solution and reconstitute a fresh vial. For long-term storage, keep peptides in lyophilised form at -20°C rather than freezing reconstituted solutions.